{"id": "article-24580_0", "title": "Lymphoma -- Continuing Education Activity", "content": "Lymphoma comprises heterogeneous malignancies that arise from the clonal proliferation of lymphocytes. It represents approximately 5% of malignancies. Overall survival is estimated to be 72%. This activity outlines the evaluation and management of lymphoma and highlights the role of the interprofessional team in managing patients with this condition.", "contents": "Lymphoma -- Continuing Education Activity. Lymphoma comprises heterogeneous malignancies that arise from the clonal proliferation of lymphocytes. It represents approximately 5% of malignancies. Overall survival is estimated to be 72%. This activity outlines the evaluation and management of lymphoma and highlights the role of the interprofessional team in managing patients with this condition."}
{"id": "article-24580_1", "title": "Lymphoma -- Continuing Education Activity", "content": "Objectives: Describe the etiology of the common types of lymphoma. Describe the clinical presentation of the common types of lymphoma. Outline the treatment plan of the common types of lymphoma. Access free multiple choice questions on this topic.", "contents": "Lymphoma -- Continuing Education Activity. Objectives: Describe the etiology of the common types of lymphoma. Describe the clinical presentation of the common types of lymphoma. Outline the treatment plan of the common types of lymphoma. Access free multiple choice questions on this topic."}
{"id": "article-24580_2", "title": "Lymphoma -- Introduction", "content": "Lymphomas are a heterogeneous group of malignancies that arise from the clonal proliferation of B- cell, T- cell and natural killer (NK) cell subsets of lymphocytes at different stages of maturation. [1] [2] Lymphoma comprises heterogeneous malignancies that arise from the clonal proliferation of lymphocytes. It represents approximately 5% of malignancies. Overall survival is estimated to be 72%.", "contents": "Lymphoma -- Introduction. Lymphomas are a heterogeneous group of malignancies that arise from the clonal proliferation of B- cell, T- cell and natural killer (NK) cell subsets of lymphocytes at different stages of maturation. [1] [2] Lymphoma comprises heterogeneous malignancies that arise from the clonal proliferation of lymphocytes. It represents approximately 5% of malignancies. Overall survival is estimated to be 72%."}
{"id": "article-24580_3", "title": "Lymphoma -- Etiology", "content": "Different environmental, infectious, and genetic factors have been identified, which predispose to lymphoma. Occupational exposure: herbicides, pesticides", "contents": "Lymphoma -- Etiology. Different environmental, infectious, and genetic factors have been identified, which predispose to lymphoma. Occupational exposure: herbicides, pesticides"}
{"id": "article-24580_4", "title": "Lymphoma -- Etiology", "content": "Infectious organisms: These include Helicobacter pylori (MALT lymphoma), Borrelia burgdorferi , Chlamydia psittaci , Campylobacter jejuni , human T- cell lymphotropic virus (adult T- cell leukemia/lymphoma), hepatitis C ( lymphoplasmacytic lymphoma, diffuse large B-cell lymphoma and marginal zone lymphoma), human herpesvirus 8 (primary effusion lymphoma and Castleman disease). Chronic stimulation of lymphoid tissue also increases the risk of lymphoma development. Persistent infection with viruses like Epstein Barr virus and cytomegalovirus also predisposes to the development of lymphoma. [3] [4] Immunodeficiency: HIV infection, transplant recipients, and those with genetic immunodeficiency disorders (severe combined immunodeficiency and common variable immunodeficiency). [5]", "contents": "Lymphoma -- Etiology. Infectious organisms: These include Helicobacter pylori (MALT lymphoma), Borrelia burgdorferi , Chlamydia psittaci , Campylobacter jejuni , human T- cell lymphotropic virus (adult T- cell leukemia/lymphoma), hepatitis C ( lymphoplasmacytic lymphoma, diffuse large B-cell lymphoma and marginal zone lymphoma), human herpesvirus 8 (primary effusion lymphoma and Castleman disease). Chronic stimulation of lymphoid tissue also increases the risk of lymphoma development. Persistent infection with viruses like Epstein Barr virus and cytomegalovirus also predisposes to the development of lymphoma. [3] [4] Immunodeficiency: HIV infection, transplant recipients, and those with genetic immunodeficiency disorders (severe combined immunodeficiency and common variable immunodeficiency). [5]"}
{"id": "article-24580_5", "title": "Lymphoma -- Etiology", "content": "Drugs: Tumour necrosis factor-alpha inhibitors are associated in particular with T- cell lymphoma. Chronic immunosuppression in post-transplant patients (both solid organ transplant and bone marrow transplant recipients) increases the risk of lymphoma. Autoimmune diseases: Inflammatory bowel disease (enteropathy associated lymphoma), rheumatoid arthritis and, Sj\u00f6gren\u2019s syndrome (diffuse large B-cell lymphoma) Geographic location: Extranodal NK/T- cell lymphoma incidence is high in Southern Asia and some parts of Latin America. [1] [2]", "contents": "Lymphoma -- Etiology. Drugs: Tumour necrosis factor-alpha inhibitors are associated in particular with T- cell lymphoma. Chronic immunosuppression in post-transplant patients (both solid organ transplant and bone marrow transplant recipients) increases the risk of lymphoma. Autoimmune diseases: Inflammatory bowel disease (enteropathy associated lymphoma), rheumatoid arthritis and, Sj\u00f6gren\u2019s syndrome (diffuse large B-cell lymphoma) Geographic location: Extranodal NK/T- cell lymphoma incidence is high in Southern Asia and some parts of Latin America. [1] [2]"}
{"id": "article-24580_6", "title": "Lymphoma -- Epidemiology", "content": "The incidence of lymphoma in the United States from 2009 to 2013 was 22/ 100,000, representing approximately 5% of malignancies, it doubled in the time period 1970-1990, and it has been stable since. The median age of diagnosis is 63. Overall survival is estimated to be 72% at five years, and it is improving. [1] Lymphomas are broadly classified into Hodgkin lymphoma (HL), 10% and Non- Hodgkin lymphoma (NHL), 90%. HL is further classified into classical and non-classical types and NHL into B- cell, T- cell and natural killer (NK) cell types. For clinical purposes, lymphoma is termed as aggressive (high grade) and indolent (low grade). [6] Below is the revised 2016 revised WHO classification of lymphomas. [7]", "contents": "Lymphoma -- Epidemiology. The incidence of lymphoma in the United States from 2009 to 2013 was 22/ 100,000, representing approximately 5% of malignancies, it doubled in the time period 1970-1990, and it has been stable since. The median age of diagnosis is 63. Overall survival is estimated to be 72% at five years, and it is improving. [1] Lymphomas are broadly classified into Hodgkin lymphoma (HL), 10% and Non- Hodgkin lymphoma (NHL), 90%. HL is further classified into classical and non-classical types and NHL into B- cell, T- cell and natural killer (NK) cell types. For clinical purposes, lymphoma is termed as aggressive (high grade) and indolent (low grade). [6] Below is the revised 2016 revised WHO classification of lymphomas. [7]"}
{"id": "article-24580_7", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Chronic lymphocytic leukemia/small lymphocytic lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Chronic lymphocytic leukemia/small lymphocytic lymphoma"}
{"id": "article-24580_8", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Monoclonal B-cell lymphocytosis", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Monoclonal B-cell lymphocytosis"}
{"id": "article-24580_9", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "B-cell prolymphocytic leukemia", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. B-cell prolymphocytic leukemia"}
{"id": "article-24580_10", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Splenic marginal zone lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Splenic marginal zone lymphoma"}
{"id": "article-24580_11", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Hairy cell leukemia", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Hairy cell leukemia"}
{"id": "article-24580_12", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Splenic B-cell lymphoma/leukemia, unclassifiable Splenic diffuse red pulp small B-cell lymphoma Hairy cell leukemia-variant", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Splenic B-cell lymphoma/leukemia, unclassifiable Splenic diffuse red pulp small B-cell lymphoma Hairy cell leukemia-variant"}
{"id": "article-24580_13", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Lymphoplasmacytic lymphoma Waldenstr\u00f6m macroglobulinemia", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Lymphoplasmacytic lymphoma Waldenstr\u00f6m macroglobulinemia"}
{"id": "article-24580_14", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Monoclonal gammopathy of undetermined significance (MGUS), IgM", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Monoclonal gammopathy of undetermined significance (MGUS), IgM"}
{"id": "article-24580_15", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "\u03bc heavy-chain disease", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. \u03bc heavy-chain disease"}
{"id": "article-24580_16", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "\u03b3 heavy-chain disease", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. \u03b3 heavy-chain disease"}
{"id": "article-24580_17", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "\u03b1 heavy-chain disease", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. \u03b1 heavy-chain disease"}
{"id": "article-24580_18", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Monoclonal gammopathy of undetermined significance (MGUS), IgG/A", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Monoclonal gammopathy of undetermined significance (MGUS), IgG/A"}
{"id": "article-24580_19", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Plasma cell myeloma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Plasma cell myeloma"}
{"id": "article-24580_20", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Solitary plasmacytoma of bone", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Solitary plasmacytoma of bone"}
{"id": "article-24580_21", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Extraosseous plasmacytoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Extraosseous plasmacytoma"}
{"id": "article-24580_22", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Monoclonal immunoglobulin deposition diseases", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Monoclonal immunoglobulin deposition diseases"}
{"id": "article-24580_23", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)"}
{"id": "article-24580_24", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Nodal marginal zone lymphoma Pediatric nodal marginal zone lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Nodal marginal zone lymphoma Pediatric nodal marginal zone lymphoma"}
{"id": "article-24580_25", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Follicular lymphoma In situ follicular neoplasia", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Follicular lymphoma In situ follicular neoplasia"}
{"id": "article-24580_26", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Duodenal-type follicular lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Duodenal-type follicular lymphoma"}
{"id": "article-24580_27", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Pediatric-type follicular lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Pediatric-type follicular lymphoma"}
{"id": "article-24580_28", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Large B-cell lymphoma with IRF4 rearrangement", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Large B-cell lymphoma with IRF4 rearrangement"}
{"id": "article-24580_29", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Primary cutaneous follicle center lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Primary cutaneous follicle center lymphoma"}
{"id": "article-24580_30", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Mantle cell lymphoma In situ mantle cell neoplasia", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Mantle cell lymphoma In situ mantle cell neoplasia"}
{"id": "article-24580_31", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type Activated B-cell type", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type Activated B-cell type"}
{"id": "article-24580_32", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "T-cell/histiocyte-rich large B-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. T-cell/histiocyte-rich large B-cell lymphoma"}
{"id": "article-24580_33", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Primary DLBCL of the central nervous system (CNS)", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Primary DLBCL of the central nervous system (CNS)"}
{"id": "article-24580_34", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Primary cutaneous DLBCL, leg type", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Primary cutaneous DLBCL, leg type"}
{"id": "article-24580_35", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "EBV+ DLBCL, NOS", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. EBV+ DLBCL, NOS"}
{"id": "article-24580_36", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "EBV+mucocutaneous ulcer", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. EBV+mucocutaneous ulcer"}
{"id": "article-24580_37", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "DLBCL associated with chronic inflammation", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. DLBCL associated with chronic inflammation"}
{"id": "article-24580_38", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Lymphomatoid granulomatosis", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Lymphomatoid granulomatosis"}
{"id": "article-24580_39", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Primary mediastinal (thymic) large B-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Primary mediastinal (thymic) large B-cell lymphoma"}
{"id": "article-24580_40", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Intravascular large B-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Intravascular large B-cell lymphoma"}
{"id": "article-24580_41", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "ALK+ large B-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. ALK+ large B-cell lymphoma"}
{"id": "article-24580_42", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Plasmablastic lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Plasmablastic lymphoma"}
{"id": "article-24580_43", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Primary effusion lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Primary effusion lymphoma"}
{"id": "article-24580_44", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "HHV8+DLBCL, NOS", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. HHV8+DLBCL, NOS"}
{"id": "article-24580_45", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Burkitt lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Burkitt lymphoma"}
{"id": "article-24580_46", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "Burkitt-like lymphoma with 11q aberration", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. Burkitt-like lymphoma with 11q aberration"}
{"id": "article-24580_47", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements"}
{"id": "article-24580_48", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "High-grade B-cell lymphoma, NOS", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. High-grade B-cell lymphoma, NOS"}
{"id": "article-24580_49", "title": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms", "content": "B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature B-cell neoplasms. B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma"}
{"id": "article-24580_50", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "T-cell prolymphocytic leukemia", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. T-cell prolymphocytic leukemia"}
{"id": "article-24580_51", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "T-cell large granular lymphocytic leukemia", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. T-cell large granular lymphocytic leukemia"}
{"id": "article-24580_52", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Chronic lymphoproliferative disorder of NK cells", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Chronic lymphoproliferative disorder of NK cells"}
{"id": "article-24580_53", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Aggressive NK-cell leukemia", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Aggressive NK-cell leukemia"}
{"id": "article-24580_54", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Systemic EBV+ T-cell lymphoma of childhood", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Systemic EBV+ T-cell lymphoma of childhood"}
{"id": "article-24580_55", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Hydroa vacciniforme\u2013like lymphoproliferative disorder", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Hydroa vacciniforme\u2013like lymphoproliferative disorder"}
{"id": "article-24580_56", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Adult T-cell leukemia/lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Adult T-cell leukemia/lymphoma"}
{"id": "article-24580_57", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Extranodal NK-/T-cell lymphoma, nasal type", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Extranodal NK-/T-cell lymphoma, nasal type"}
{"id": "article-24580_58", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Enteropathy-associated T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Enteropathy-associated T-cell lymphoma"}
{"id": "article-24580_59", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Monomorphic epitheliotropic intestinal T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Monomorphic epitheliotropic intestinal T-cell lymphoma"}
{"id": "article-24580_60", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Indolent T-cell lymphoproliferative disorder of the GI tract", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Indolent T-cell lymphoproliferative disorder of the GI tract"}
{"id": "article-24580_61", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Hepatosplenic T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Hepatosplenic T-cell lymphoma"}
{"id": "article-24580_62", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Subcutaneous panniculitis-like T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Subcutaneous panniculitis-like T-cell lymphoma"}
{"id": "article-24580_63", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Mycosis fungoides", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Mycosis fungoides"}
{"id": "article-24580_64", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "S\u00e9zary syndrome", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. S\u00e9zary syndrome"}
{"id": "article-24580_65", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Primary cutaneous CD30+ T-cell lymphoproliferative disorders Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Primary cutaneous CD30+ T-cell lymphoproliferative disorders Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma"}
{"id": "article-24580_66", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Primary cutaneous \u03b3\u03b4 T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Primary cutaneous \u03b3\u03b4 T-cell lymphoma"}
{"id": "article-24580_67", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Primary cutaneous CD8+aggressive epidermotropic cytotoxic T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Primary cutaneous CD8+aggressive epidermotropic cytotoxic T-cell lymphoma"}
{"id": "article-24580_68", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Primary cutaneous acral CD8+T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Primary cutaneous acral CD8+T-cell lymphoma"}
{"id": "article-24580_69", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Primary cutaneous CD4+small/medium T-cell lymphoproliferative disorder", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Primary cutaneous CD4+small/medium T-cell lymphoproliferative disorder"}
{"id": "article-24580_70", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Peripheral T-cell lymphoma, NOS", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Peripheral T-cell lymphoma, NOS"}
{"id": "article-24580_71", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Angioimmunoblastic T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Angioimmunoblastic T-cell lymphoma"}
{"id": "article-24580_72", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Follicular T-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Follicular T-cell lymphoma"}
{"id": "article-24580_73", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Nodal peripheral T-cell lymphoma with TFH phenotype", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Nodal peripheral T-cell lymphoma with TFH phenotype"}
{"id": "article-24580_74", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Anaplastic large-cell lymphoma, ALK+", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Anaplastic large-cell lymphoma, ALK+"}
{"id": "article-24580_75", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Anaplastic large-cell lymphoma, ALK\u2212", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Anaplastic large-cell lymphoma, ALK\u2212"}
{"id": "article-24580_76", "title": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms", "content": "Breast implant-associated anaplastic large-cell lymphoma", "contents": "Lymphoma -- Epidemiology -- Mature T and NK neoplasms. Breast implant-associated anaplastic large-cell lymphoma"}
{"id": "article-24580_77", "title": "Lymphoma -- Epidemiology -- Hodgkin lymphoma", "content": "Nodular lymphocyte-predominant Hodgkin lymphoma Classical Hodgkin lymphoma Nodular sclerosis classical Hodgkin lymphoma Lymphocyte-rich classical Hodgkin lymphoma Mixed cellularity classical Hodgkin lymphoma Lymphocyte-depleted classical Hodgkin lymphoma", "contents": "Lymphoma -- Epidemiology -- Hodgkin lymphoma. Nodular lymphocyte-predominant Hodgkin lymphoma Classical Hodgkin lymphoma Nodular sclerosis classical Hodgkin lymphoma Lymphocyte-rich classical Hodgkin lymphoma Mixed cellularity classical Hodgkin lymphoma Lymphocyte-depleted classical Hodgkin lymphoma"}
{"id": "article-24580_78", "title": "Lymphoma -- Epidemiology -- Posttransplant lymphoproliferative disorders (PTLD)", "content": "Plasmacytic hyperplasia PTLD Infectious mononucleosis PTLD Florid follicular hyperplasia PTLD Polymorphic PTLD Monomorphic PTLD (B- and T-/NK-cell types) Classical Hodgkin lymphoma PTLD", "contents": "Lymphoma -- Epidemiology -- Posttransplant lymphoproliferative disorders (PTLD). Plasmacytic hyperplasia PTLD Infectious mononucleosis PTLD Florid follicular hyperplasia PTLD Polymorphic PTLD Monomorphic PTLD (B- and T-/NK-cell types) Classical Hodgkin lymphoma PTLD"}
{"id": "article-24580_79", "title": "Lymphoma -- Pathophysiology", "content": "Different stressors in the form of infectious, inflammatory, and toxic factors interact with the genetic makeup of the human host in a complex manner to result in lymphomagenesis. [1] [2] One of the widely accepted principles of lymphomagenesis is being on long term immunosuppressive therapies, which makes the innate immune system less able to detect and destroy cancer cells or ward off infections that could result in cancers.", "contents": "Lymphoma -- Pathophysiology. Different stressors in the form of infectious, inflammatory, and toxic factors interact with the genetic makeup of the human host in a complex manner to result in lymphomagenesis. [1] [2] One of the widely accepted principles of lymphomagenesis is being on long term immunosuppressive therapies, which makes the innate immune system less able to detect and destroy cancer cells or ward off infections that could result in cancers."}
{"id": "article-24580_80", "title": "Lymphoma -- Histopathology", "content": "A diagnosis of lymphoma is confirmed by tissue biopsy, and commonly used methods include fine-needle aspiration, core biopsy, incision/wedge biopsy, and excisional biopsy. Excisional biopsy is considered the\u00a0\"gold standard\" as it allows for the assessment of whole lymph node architecture. The different pathologic characteristics and histologic patterns of common lymphomas are as below.", "contents": "Lymphoma -- Histopathology. A diagnosis of lymphoma is confirmed by tissue biopsy, and commonly used methods include fine-needle aspiration, core biopsy, incision/wedge biopsy, and excisional biopsy. Excisional biopsy is considered the\u00a0\"gold standard\" as it allows for the assessment of whole lymph node architecture. The different pathologic characteristics and histologic patterns of common lymphomas are as below."}
{"id": "article-24580_81", "title": "Lymphoma -- Histopathology -- Hodgkin Lymphoma (HL)", "content": "HL is defined by the presence of pathological Hodgkin Reed-Sternberg (HRS) cells, which are of B-cell origin on the background of nodular sclerosis, lymphocyte-predominant, or depleted stroma. Classical HL is divided into four different types, which in decreasing order of frequency are: nodular sclerosing, mixed cellularity, lymphocyte rich, and lymphocyte depleted. Non -classical HL is of an only single type, nodular lymphocyte-predominant.", "contents": "Lymphoma -- Histopathology -- Hodgkin Lymphoma (HL). HL is defined by the presence of pathological Hodgkin Reed-Sternberg (HRS) cells, which are of B-cell origin on the background of nodular sclerosis, lymphocyte-predominant, or depleted stroma. Classical HL is divided into four different types, which in decreasing order of frequency are: nodular sclerosing, mixed cellularity, lymphocyte rich, and lymphocyte depleted. Non -classical HL is of an only single type, nodular lymphocyte-predominant."}
{"id": "article-24580_82", "title": "Lymphoma -- Histopathology -- Hodgkin Lymphoma (HL)", "content": "HL presentation is bimodal with one age peak in the early 20s and second in the mid-60s. \u00a0For most cases, no underlying cause is found, but for some subtypes of classical HL, a significant number of patients test positive for EBV. The causative relationship between EBV and HL been investigated extensively. Other risk factors are genetic predisposition (high incidence among patient's relatives), immunodeficiency states, and environmental factors (high incidence in farmers, woodworkers, and meat processors).", "contents": "Lymphoma -- Histopathology -- Hodgkin Lymphoma (HL). HL presentation is bimodal with one age peak in the early 20s and second in the mid-60s. \u00a0For most cases, no underlying cause is found, but for some subtypes of classical HL, a significant number of patients test positive for EBV. The causative relationship between EBV and HL been investigated extensively. Other risk factors are genetic predisposition (high incidence among patient's relatives), immunodeficiency states, and environmental factors (high incidence in farmers, woodworkers, and meat processors)."}
{"id": "article-24580_83", "title": "Lymphoma -- Histopathology -- Hodgkin Lymphoma (HL)", "content": "Histologic features of HL: are HRS cells, which are odd-looking large, bilobed cells with two nuclei, appearing within a background of non-malignant inflammatory cells. Immunohistochemical staining of HL shows positive markers for CD30, CD15, but negative for CD20, making it difficult to determine the B-cell lineage. [1] [2] [7]", "contents": "Lymphoma -- Histopathology -- Hodgkin Lymphoma (HL). Histologic features of HL: are HRS cells, which are odd-looking large, bilobed cells with two nuclei, appearing within a background of non-malignant inflammatory cells. Immunohistochemical staining of HL shows positive markers for CD30, CD15, but negative for CD20, making it difficult to determine the B-cell lineage. [1] [2] [7]"}
{"id": "article-24580_84", "title": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL)", "content": "It is the most common NHL, accounting for 25% to 30% of cases. \u00a0It is a clinically aggressive lymphoma. DLBCL often arises in the lymph nodes but can also present anywhere else in the body, and the gastrointestinal tract is the most common system outside the lymphatic system. Other common involvement sites are testes, eyes, and central nervous system.", "contents": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL). It is the most common NHL, accounting for 25% to 30% of cases. \u00a0It is a clinically aggressive lymphoma. DLBCL often arises in the lymph nodes but can also present anywhere else in the body, and the gastrointestinal tract is the most common system outside the lymphatic system. Other common involvement sites are testes, eyes, and central nervous system."}
{"id": "article-24580_85", "title": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL)", "content": "When an extranodal disease is present with minimal or no lymph node involvement, the disease is considered primary extranodal DLBCL, whereas when both nodal and extranodal disease is present, the disease is considered nodal lymphoma.", "contents": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL). When an extranodal disease is present with minimal or no lymph node involvement, the disease is considered primary extranodal DLBCL, whereas when both nodal and extranodal disease is present, the disease is considered nodal lymphoma."}
{"id": "article-24580_86", "title": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL)", "content": "It is classified based on gene expression into three categories\u00a0according to the cell of origin: germinal center B cell-like, activated B cell-like, and type 3; the last two have unfavorable prognosis.", "contents": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL). It is classified based on gene expression into three categories\u00a0according to the cell of origin: germinal center B cell-like, activated B cell-like, and type 3; the last two have unfavorable prognosis."}
{"id": "article-24580_87", "title": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL)", "content": "Low-grade lymphomas like follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma can develop into high-grade through a transformation of disease into DLBCL, which is triggered by accumulation of additional transforming mutations.", "contents": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL). Low-grade lymphomas like follicular lymphoma, small lymphocytic lymphoma, marginal zone lymphoma, and lymphoplasmacytic lymphoma can develop into high-grade through a transformation of disease into DLBCL, which is triggered by accumulation of additional transforming mutations."}
{"id": "article-24580_88", "title": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL)", "content": "Histologic features: include areas of diffuse involvement by large lymphoid cells that stain positive for B-cell markers CD20 and CD19. The proliferation index, determined by staining with Ki67 antibody is moderate to high. [1] [2] [7]", "contents": "Lymphoma -- Histopathology -- Diffuse large B Cell lymphoma (DLBCL). Histologic features: include areas of diffuse involvement by large lymphoid cells that stain positive for B-cell markers CD20 and CD19. The proliferation index, determined by staining with Ki67 antibody is moderate to high. [1] [2] [7]"}
{"id": "article-24580_89", "title": "Lymphoma -- Histopathology -- Follicular Lymphoma (FL)", "content": "It is an indolent lymphoma and accounts for about 20% of lymphoma diagnoses, making it the second most common lymphoma. Overall survival ranges from 8-15 years. It originates from the follicular cells in the germinal center of the lymph node. The tumor cells have overexpression of the anti-apoptotic protein BCL-2, due to translocation of the BCL-2 gene on chromosome 14 to the immunoglobulin or B-cell receptor gene on chromosome 18, t(14:18). It can transform into more aggressive DLBCL in some cases. [1] [2]", "contents": "Lymphoma -- Histopathology -- Follicular Lymphoma (FL). It is an indolent lymphoma and accounts for about 20% of lymphoma diagnoses, making it the second most common lymphoma. Overall survival ranges from 8-15 years. It originates from the follicular cells in the germinal center of the lymph node. The tumor cells have overexpression of the anti-apoptotic protein BCL-2, due to translocation of the BCL-2 gene on chromosome 14 to the immunoglobulin or B-cell receptor gene on chromosome 18, t(14:18). It can transform into more aggressive DLBCL in some cases. [1] [2]"}
{"id": "article-24580_90", "title": "Lymphoma -- Histopathology -- Follicular Lymphoma (FL)", "content": "Histologic features: histologic diagnosis requires areas of considerable follicular proliferation and expansion within the lymph node. Within the expanded lymph node follicles,\u00a0 small and large cells proliferate (similar to reactive lymph node), but instead of a\u00a0 combination of B cells (CD20+) and some T cells (CD3+), the follicles are composed mostly of B cells positive for BCL-2 in FL. However, in FL, as in a reactive node, there is a difference in the size of follicle B cells, small cells, which are called centrocytes and large cells called centroblasts. The proportion of large cells, centroblasts, is measured as being either greater than or less than 15 cells per high-power field (HPF). The larger the number of centroblasts, the higher the grade; in grades I and II, there are 0 to 15 centroblasts/HPF, whereas, in grade III, there are more than 15 centroblasts/HPF. The difference between grade IIIA and grade IIIB is the presence of a mixture of centrocytes and centroblasts in all follicles in grade IIIA, whereas, in grade IIIB, follicles consist exclusively of centroblasts, immunoblasts (activated lymphocytes), or both. Of note, FL grade IIIB is managed the same way as DLBCL. [1] [2] [7]", "contents": "Lymphoma -- Histopathology -- Follicular Lymphoma (FL). Histologic features: histologic diagnosis requires areas of considerable follicular proliferation and expansion within the lymph node. Within the expanded lymph node follicles,\u00a0 small and large cells proliferate (similar to reactive lymph node), but instead of a\u00a0 combination of B cells (CD20+) and some T cells (CD3+), the follicles are composed mostly of B cells positive for BCL-2 in FL. However, in FL, as in a reactive node, there is a difference in the size of follicle B cells, small cells, which are called centrocytes and large cells called centroblasts. The proportion of large cells, centroblasts, is measured as being either greater than or less than 15 cells per high-power field (HPF). The larger the number of centroblasts, the higher the grade; in grades I and II, there are 0 to 15 centroblasts/HPF, whereas, in grade III, there are more than 15 centroblasts/HPF. The difference between grade IIIA and grade IIIB is the presence of a mixture of centrocytes and centroblasts in all follicles in grade IIIA, whereas, in grade IIIB, follicles consist exclusively of centroblasts, immunoblasts (activated lymphocytes), or both. Of note, FL grade IIIB is managed the same way as DLBCL. [1] [2] [7]"}
{"id": "article-24580_91", "title": "Lymphoma -- Histopathology -- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue", "content": "Normal mucosal tissue contains non-continuously spread collections of lymphocytes called mucosa-associated lymphoid tissue (MALT). Lymphoma that originates from the marginal zone of such collection is called MALT lymphoma and constitutes 7% of all lymphomas. It is a slow-growing B-cell lymphoma. Repeated antigen stimulation in the setting of infection, autoimmune disease, or other inflammatory condition predisposes to the pathogenesis. Some well-known associations are H.pylori (gastric), C. psitacci (ocular), C. jejuni (small intestine), B. burgdorferi (skin), Hashimoto thyroiditis (thyroid) and Sj\u00f6gren syndrome (salivary gland). It originates from a marginal zone cell, a B-cell. [1] [2] [7] [2] Histologic features: Aggregates of small lymphocytes with IHC staining positive for CD20 and negative CD5 and CD10. [1] [2] [7]", "contents": "Lymphoma -- Histopathology -- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. Normal mucosal tissue contains non-continuously spread collections of lymphocytes called mucosa-associated lymphoid tissue (MALT). Lymphoma that originates from the marginal zone of such collection is called MALT lymphoma and constitutes 7% of all lymphomas. It is a slow-growing B-cell lymphoma. Repeated antigen stimulation in the setting of infection, autoimmune disease, or other inflammatory condition predisposes to the pathogenesis. Some well-known associations are H.pylori (gastric), C. psitacci (ocular), C. jejuni (small intestine), B. burgdorferi (skin), Hashimoto thyroiditis (thyroid) and Sj\u00f6gren syndrome (salivary gland). It originates from a marginal zone cell, a B-cell. [1] [2] [7] [2] Histologic features: Aggregates of small lymphocytes with IHC staining positive for CD20 and negative CD5 and CD10. [1] [2] [7]"}
{"id": "article-24580_92", "title": "Lymphoma -- Histopathology -- Mantle Cell Lymphoma", "content": "It comprises 6% of lymphomas. It has the worst prognosis among all lymphoma subtypes with a median overall survival of 5 years. Despite that, it has a wide range of presentations, and in some older patients, it has a very slowly progressive course where close surveillance without immediate treatment initiation has been used. It has a male predominance. It usually presents as a widespread disease; bone marrow and gastrointestinal tract are the most common sites of involvement. In the gastrointestinal tract, it can cause obstruction due to the formation of multiple polyps, a condition called lymphomatous polyposis.", "contents": "Lymphoma -- Histopathology -- Mantle Cell Lymphoma. It comprises 6% of lymphomas. It has the worst prognosis among all lymphoma subtypes with a median overall survival of 5 years. Despite that, it has a wide range of presentations, and in some older patients, it has a very slowly progressive course where close surveillance without immediate treatment initiation has been used. It has a male predominance. It usually presents as a widespread disease; bone marrow and gastrointestinal tract are the most common sites of involvement. In the gastrointestinal tract, it can cause obstruction due to the formation of multiple polyps, a condition called lymphomatous polyposis."}
{"id": "article-24580_93", "title": "Lymphoma -- Histopathology -- Mantle Cell Lymphoma", "content": "Histologic features: lt arises from the mantle zone cell of the lymph node, which is a post\u2013GC (germinal center) B-cell. Histologic diagnosis is made by visualizing areas of small lymphoid cells, arising from mantle zone directly in some cases, with characteristic IHC staining and being always positive for cyclin D1, a protein involved in cell cycle regulation. It results from a translocation of the gene encoding for cyclinD1 on chromosome 11 and the one encoding for Ig (immunoglobulin) on chromosome 14, t(11;14). [1] [2] [7]", "contents": "Lymphoma -- Histopathology -- Mantle Cell Lymphoma. Histologic features: lt arises from the mantle zone cell of the lymph node, which is a post\u2013GC (germinal center) B-cell. Histologic diagnosis is made by visualizing areas of small lymphoid cells, arising from mantle zone directly in some cases, with characteristic IHC staining and being always positive for cyclin D1, a protein involved in cell cycle regulation. It results from a translocation of the gene encoding for cyclinD1 on chromosome 11 and the one encoding for Ig (immunoglobulin) on chromosome 14, t(11;14). [1] [2] [7]"}
{"id": "article-24580_94", "title": "Lymphoma -- Histopathology -- Burkitt Lymphoma (BL)", "content": "It was first described by the Irish surgeon Denis Burkitt in 1958 and is a very aggressive B-cell lymphoma. It is divided into three types: endemic, spontaneous, and immunodeficiency associated. The endemic form of BL is a pediatric tumor in Africa, usually presenting as a mandibular mass and is strongly associated with chronic EBV infection. In the United States, spontaneous BL is the most common form and usually presents as an abdominal mass or lymphadenopathy. Immunodeficiency associated BL is seen in HIV infection, and its presence can be an AIDS-defining condition. The pathogenesis is caused by translocation of the cell proliferation proto-oncogene, C-Myc to one of the sites encoding Ig expression, either the heavy chain t(8;14) or one of the two light chains, t(2;8) or t( 8;22).", "contents": "Lymphoma -- Histopathology -- Burkitt Lymphoma (BL). It was first described by the Irish surgeon Denis Burkitt in 1958 and is a very aggressive B-cell lymphoma. It is divided into three types: endemic, spontaneous, and immunodeficiency associated. The endemic form of BL is a pediatric tumor in Africa, usually presenting as a mandibular mass and is strongly associated with chronic EBV infection. In the United States, spontaneous BL is the most common form and usually presents as an abdominal mass or lymphadenopathy. Immunodeficiency associated BL is seen in HIV infection, and its presence can be an AIDS-defining condition. The pathogenesis is caused by translocation of the cell proliferation proto-oncogene, C-Myc to one of the sites encoding Ig expression, either the heavy chain t(8;14) or one of the two light chains, t(2;8) or t( 8;22)."}
{"id": "article-24580_95", "title": "Lymphoma -- Histopathology -- Burkitt Lymphoma (BL)", "content": "Histologic features: histologic diagnosis is made by recognizing medium to large B-cells with a very high proliferation rate (Ki67 of almost 100%), with the classic starry sky appearance due to tingible body macrophages with surrounding clearing. [1] [2] [7]", "contents": "Lymphoma -- Histopathology -- Burkitt Lymphoma (BL). Histologic features: histologic diagnosis is made by recognizing medium to large B-cells with a very high proliferation rate (Ki67 of almost 100%), with the classic starry sky appearance due to tingible body macrophages with surrounding clearing. [1] [2] [7]"}
{"id": "article-24580_96", "title": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas", "content": "The peripheral T-cell lymphomas (PTCLs) are a diverse group of diseases that constitute approximately 5% to 10% of NHL.", "contents": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas. The peripheral T-cell lymphomas (PTCLs) are a diverse group of diseases that constitute approximately 5% to 10% of NHL."}
{"id": "article-24580_97", "title": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas", "content": "The PTCLs are classified into three main categories with predominantly leukemic, nodal, or extranodal involvement. The first subset of the peripheral T-cell lymphomas frequently presents with a leukemic phase. It includes T-cell prolymphocytic leukemia, T-cell large granular lymphocytic (LGL) leukemia, natural killer/T (NK/T)-cell leukemia, and adult T cell leukemia/ lymphoma. The second set presents with adenopathy, and it includes angioimmunoblastic T- cell lymphoma (AITL), systemic anaplastic large cell lymphoma (ALCL), and peripheral T- cell lymphoma (PTCL).", "contents": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas. The PTCLs are classified into three main categories with predominantly leukemic, nodal, or extranodal involvement. The first subset of the peripheral T-cell lymphomas frequently presents with a leukemic phase. It includes T-cell prolymphocytic leukemia, T-cell large granular lymphocytic (LGL) leukemia, natural killer/T (NK/T)-cell leukemia, and adult T cell leukemia/ lymphoma. The second set presents with adenopathy, and it includes angioimmunoblastic T- cell lymphoma (AITL), systemic anaplastic large cell lymphoma (ALCL), and peripheral T- cell lymphoma (PTCL)."}
{"id": "article-24580_98", "title": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas", "content": "The extranodal PTCLs include mycosis fungoides (MF) and cutaneous ALCL. \u00a0These have chronic and slow progression with long term remission. Sezary syndrome represents the leukemic transformation of MF, presenting with abnormal circulating lymphocytes (Sezary cells), adenopathy, and erythroderma and has a worse prognosis.", "contents": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas. The extranodal PTCLs include mycosis fungoides (MF) and cutaneous ALCL. \u00a0These have chronic and slow progression with long term remission. Sezary syndrome represents the leukemic transformation of MF, presenting with abnormal circulating lymphocytes (Sezary cells), adenopathy, and erythroderma and has a worse prognosis."}
{"id": "article-24580_99", "title": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas", "content": "Extranodal NK/T-cell lymphoma, nasal type (nasal NK/T lymphoma) is an aggressive lymphoma that is the most common cause of the \"lethal midline granuloma\" syndrome. It is strongly associated with EBV infection and is frequently seen in East Asia and among the indigenous population in Peru. It affects both children and adults and presents as a locally invasive disease presenting with nasal obstruction and destruction of nasal passages, hard palate, and sinuses [1] [2] [7] [8]", "contents": "Lymphoma -- Histopathology -- Peripheral T Cell lymphomas. Extranodal NK/T-cell lymphoma, nasal type (nasal NK/T lymphoma) is an aggressive lymphoma that is the most common cause of the \"lethal midline granuloma\" syndrome. It is strongly associated with EBV infection and is frequently seen in East Asia and among the indigenous population in Peru. It affects both children and adults and presents as a locally invasive disease presenting with nasal obstruction and destruction of nasal passages, hard palate, and sinuses [1] [2] [7] [8]"}
{"id": "article-24580_100", "title": "Lymphoma -- History and Physical -- Hodgkin Lymphoma", "content": "Usually presents with painless, superficial enlarged lymphadenopathy, which involves contiguous lymph node chains in a predictable manner with the spread of the disease. Later in the disease course, hematogenous spread occurs with vascular invasion. The majority of patients present with supradiaphragmatic disease and isolated infra-diaphragmatic disease occurs in only 3-7% of patients. Approximately 60\u00a0to 70% of patients present with cervical and/or supraclavicular lymphadenopathy, 30% with the axillary disease, 50\u00a0to 60% with mediastinal involvement seen on radiology in the absence of symptoms. Infra diaphragmatic disease involves para-aortic lymph nodes, but the involvement of abdominal organs is uncommon. Only 10-15 % of patients with HL have extranodal disease, and the commonly affected organs are bone, bone marrow, lung, and liver. CNS involvement is very rare, but extension from para-aortic adenopathy into epidural space can result in neurological symptoms. [1] [2] [9]", "contents": "Lymphoma -- History and Physical -- Hodgkin Lymphoma. Usually presents with painless, superficial enlarged lymphadenopathy, which involves contiguous lymph node chains in a predictable manner with the spread of the disease. Later in the disease course, hematogenous spread occurs with vascular invasion. The majority of patients present with supradiaphragmatic disease and isolated infra-diaphragmatic disease occurs in only 3-7% of patients. Approximately 60\u00a0to 70% of patients present with cervical and/or supraclavicular lymphadenopathy, 30% with the axillary disease, 50\u00a0to 60% with mediastinal involvement seen on radiology in the absence of symptoms. Infra diaphragmatic disease involves para-aortic lymph nodes, but the involvement of abdominal organs is uncommon. Only 10-15 % of patients with HL have extranodal disease, and the commonly affected organs are bone, bone marrow, lung, and liver. CNS involvement is very rare, but extension from para-aortic adenopathy into epidural space can result in neurological symptoms. [1] [2] [9]"}
{"id": "article-24580_101", "title": "Lymphoma -- History and Physical -- Hodgkin Lymphoma", "content": "Approximately 25% of patients with previously undiagnosed HL develop systemic symptoms before the development of lymphadenopathy called B symptoms (fevers, drenching night sweats, and unintentional weight loss). The presence of these symptoms carries a worse prognosis in both early and advanced-stage disease. \u00a0Other symptoms include severe pruritis and alcohol-induced pain occurring minutes after alcohol intake and localized to regions of lymphadenopathy. Some rare neurological syndromes, including cerebellar degeneration and stiff-person syndrome, also have been reported. [1] [2]", "contents": "Lymphoma -- History and Physical -- Hodgkin Lymphoma. Approximately 25% of patients with previously undiagnosed HL develop systemic symptoms before the development of lymphadenopathy called B symptoms (fevers, drenching night sweats, and unintentional weight loss). The presence of these symptoms carries a worse prognosis in both early and advanced-stage disease. \u00a0Other symptoms include severe pruritis and alcohol-induced pain occurring minutes after alcohol intake and localized to regions of lymphadenopathy. Some rare neurological syndromes, including cerebellar degeneration and stiff-person syndrome, also have been reported. [1] [2]"}
{"id": "article-24580_102", "title": "Lymphoma -- History and Physical -- Non-Hodgkin Lymphoma", "content": "DLBCL", "contents": "Lymphoma -- History and Physical -- Non-Hodgkin Lymphoma. DLBCL"}
{"id": "article-24580_103", "title": "Lymphoma -- History and Physical -- Non-Hodgkin Lymphoma", "content": "The most common complaint is symptomatic, enlarging lymph nodal mass either located centrally or peripherally. 20% of patients present with stage I disease, approximately 40% with disease limited to one side of the diaphragm (stage II), and another 20% with involvement above and below the diaphragm and 40% with the widespread disease with extranodal involvement. Common sites of extranodal spread are lung, liver, kidney, and bone marrow. This is in contrast to primary extranodal sites of origin of DLBCL, which are the gastrointestinal tract, thyroid, bone, brain, testis, kidney, liver, breast, and skin. Approximately 30% of patients will report B symptoms as well as less specific symptoms of malaise and fatigue.", "contents": "Lymphoma -- History and Physical -- Non-Hodgkin Lymphoma. The most common complaint is symptomatic, enlarging lymph nodal mass either located centrally or peripherally. 20% of patients present with stage I disease, approximately 40% with disease limited to one side of the diaphragm (stage II), and another 20% with involvement above and below the diaphragm and 40% with the widespread disease with extranodal involvement. Common sites of extranodal spread are lung, liver, kidney, and bone marrow. This is in contrast to primary extranodal sites of origin of DLBCL, which are the gastrointestinal tract, thyroid, bone, brain, testis, kidney, liver, breast, and skin. Approximately 30% of patients will report B symptoms as well as less specific symptoms of malaise and fatigue."}
{"id": "article-24580_104", "title": "Lymphoma -- History and Physical -- Follicular Lymphoma", "content": "The most common presentation is subacute, or chronic asymptomatic peripheral lymphadenopathy, which sometimes\u00a0persists or waxes and wanes over a period of years. Abdominal, pelvic, or retroperitoneal lymphadenopathy can be bulky without causing gastrointestinal or genitourinary symptoms, and nodal masses are not locally invasive and destructive. The lymph node involvement is not in an orderly manner, and early hematogenous dissemination is common.\u00a0 B-symptoms are seen in less than 20% of patients and should prompt consideration for transformation into DLBCL. [10]", "contents": "Lymphoma -- History and Physical -- Follicular Lymphoma. The most common presentation is subacute, or chronic asymptomatic peripheral lymphadenopathy, which sometimes\u00a0persists or waxes and wanes over a period of years. Abdominal, pelvic, or retroperitoneal lymphadenopathy can be bulky without causing gastrointestinal or genitourinary symptoms, and nodal masses are not locally invasive and destructive. The lymph node involvement is not in an orderly manner, and early hematogenous dissemination is common.\u00a0 B-symptoms are seen in less than 20% of patients and should prompt consideration for transformation into DLBCL. [10]"}
{"id": "article-24580_105", "title": "Lymphoma -- History and Physical -- Marginal Zone Lymphoma", "content": "Presenting symptoms related to the sites of involvement (stomach, lung, ocular adnexa, breast, thyroid, bowel, skin, and soft tissue) and B-symptoms are rare and should raise suspicion for transformed lymphoma.", "contents": "Lymphoma -- History and Physical -- Marginal Zone Lymphoma. Presenting symptoms related to the sites of involvement (stomach, lung, ocular adnexa, breast, thyroid, bowel, skin, and soft tissue) and B-symptoms are rare and should raise suspicion for transformed lymphoma."}
{"id": "article-24580_106", "title": "Lymphoma -- History and Physical -- Mantle Cell Lymphoma", "content": "70% to 90% of patients present with detectable stage 4 disease. Bone marrow involvement is common, and a leukemic phase is seen as frequently as 75% in some series. The gastrointestinal tract is frequently involved and can present from diffuse lymphomatous polyposis to a normal lumen with microscopic disease seen on biopsy. Other common sites of involvement are the spleen and Waldyer\u2019s ring.", "contents": "Lymphoma -- History and Physical -- Mantle Cell Lymphoma. 70% to 90% of patients present with detectable stage 4 disease. Bone marrow involvement is common, and a leukemic phase is seen as frequently as 75% in some series. The gastrointestinal tract is frequently involved and can present from diffuse lymphomatous polyposis to a normal lumen with microscopic disease seen on biopsy. Other common sites of involvement are the spleen and Waldyer\u2019s ring."}
{"id": "article-24580_107", "title": "Lymphoma -- History and Physical -- Burkitt Lymphoma", "content": "Endemic BL presents in children as a tumor of the jaw or facial bones and spreads hematogenously early in the course to extranodal sites, including kidney, testis or ovary, CNS, or meninges. Sporadic BL presents as a bulky abdominal disease involving stomach, caecum, or small intestine with associated ascites. The involvement of kidneys, ovarian or testicular organs, CNS, or meninges is common as well. Immunodeficiency related BL usually presents with lymph node involvement, but can also involve the bone marrow, CNS, or meninges and rarely may present with leukemic phase. [1] [2]", "contents": "Lymphoma -- History and Physical -- Burkitt Lymphoma. Endemic BL presents in children as a tumor of the jaw or facial bones and spreads hematogenously early in the course to extranodal sites, including kidney, testis or ovary, CNS, or meninges. Sporadic BL presents as a bulky abdominal disease involving stomach, caecum, or small intestine with associated ascites. The involvement of kidneys, ovarian or testicular organs, CNS, or meninges is common as well. Immunodeficiency related BL usually presents with lymph node involvement, but can also involve the bone marrow, CNS, or meninges and rarely may present with leukemic phase. [1] [2]"}
{"id": "article-24580_108", "title": "Lymphoma -- Evaluation", "content": "After confirming the diagnosis of lymphoma by tissue biopsy, further evaluation involves the determination of tissue where disease activity is the greatest. PET/CT scans by measuring uptake of radiolabeled fluorodeoxyglucose (FDG) are used to measure the biological activity of lymphoma. [11] [1] [2] Staging is performed before the initiation of therapy for lymphoma.", "contents": "Lymphoma -- Evaluation. After confirming the diagnosis of lymphoma by tissue biopsy, further evaluation involves the determination of tissue where disease activity is the greatest. PET/CT scans by measuring uptake of radiolabeled fluorodeoxyglucose (FDG) are used to measure the biological activity of lymphoma. [11] [1] [2] Staging is performed before the initiation of therapy for lymphoma."}
{"id": "article-24580_109", "title": "Lymphoma -- Evaluation", "content": "The clinical staging of both HL and NHL is derived from the Ann Arbor staging system. The presence or absence of B symptoms (persistent fever, weight loss in excess of 10% of body weight over six months, or night sweats) is included in the staging for lymphoma. Blood work includes lactate dehydrogenase along with complete blood counts with differential, comprehensive metabolic panel, and uric acid.", "contents": "Lymphoma -- Evaluation. The clinical staging of both HL and NHL is derived from the Ann Arbor staging system. The presence or absence of B symptoms (persistent fever, weight loss in excess of 10% of body weight over six months, or night sweats) is included in the staging for lymphoma. Blood work includes lactate dehydrogenase along with complete blood counts with differential, comprehensive metabolic panel, and uric acid."}
{"id": "article-24580_110", "title": "Lymphoma -- Evaluation", "content": "Whole-body PET/CT imaging is preferred over CT of the chest, abdomen, and pelvis. Bone marrow biopsy is often performed for staging but may be omitted for stage III DLBCL and HL because detection of stage IV disease over stage III does not change the treatment. [12] In some cases where the lymphoma is judged to be high risk, standard staging is supplemented by cerebrospinal fluid testing. For aggressive lymphomas like DLBCL, CNS-IPI (CNS Internal Prognostic Index) tool can be used to predict CNS relapse or progression. [13]", "contents": "Lymphoma -- Evaluation. Whole-body PET/CT imaging is preferred over CT of the chest, abdomen, and pelvis. Bone marrow biopsy is often performed for staging but may be omitted for stage III DLBCL and HL because detection of stage IV disease over stage III does not change the treatment. [12] In some cases where the lymphoma is judged to be high risk, standard staging is supplemented by cerebrospinal fluid testing. For aggressive lymphomas like DLBCL, CNS-IPI (CNS Internal Prognostic Index) tool can be used to predict CNS relapse or progression. [13]"}
{"id": "article-24580_111", "title": "Lymphoma -- Evaluation", "content": "Antigen-specificity for B and T-cells is defined by the cell-surface receptor, B-cell receptor, or T-cell receptor, respectively. T-cells are programmed for antigen recognition in the thymus. B-cells mature in the marrow and encounter foreign antigen for the first time within the lymph node germinal center (GC). As such, B-cells may be divided into GC or post-GC. Post-GC, some B-cells develop eventually into plasma cells, which secrete the soluble form of B-cell receptor, that is, immunoglobulin (Ig) or antibody. The method used for determining malignancy or clonality in B-cell lymphomas is by immunohistochemical staining for light chains to show that the sample has lymphocytes expressing all kappa or lambda light chains. It is called light chain restriction and shows the presence of lymphocytic clone. [1] [2]", "contents": "Lymphoma -- Evaluation. Antigen-specificity for B and T-cells is defined by the cell-surface receptor, B-cell receptor, or T-cell receptor, respectively. T-cells are programmed for antigen recognition in the thymus. B-cells mature in the marrow and encounter foreign antigen for the first time within the lymph node germinal center (GC). As such, B-cells may be divided into GC or post-GC. Post-GC, some B-cells develop eventually into plasma cells, which secrete the soluble form of B-cell receptor, that is, immunoglobulin (Ig) or antibody. The method used for determining malignancy or clonality in B-cell lymphomas is by immunohistochemical staining for light chains to show that the sample has lymphocytes expressing all kappa or lambda light chains. It is called light chain restriction and shows the presence of lymphocytic clone. [1] [2]"}
{"id": "article-24580_112", "title": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]", "content": "Combined modality therapy, including chemotherapy with antibody-drug conjugates and radiotherapy, is the usual standard of care. Most cases of HL are chemosensitive and overall survival is 86%.", "contents": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]. Combined modality therapy, including chemotherapy with antibody-drug conjugates and radiotherapy, is the usual standard of care. Most cases of HL are chemosensitive and overall survival is 86%."}
{"id": "article-24580_113", "title": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]", "content": "Standard treatment in the United States (US) consists of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). In Germany, the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) is more popular. A third regimen that is used is Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone). All these regimens have similar response rates with BEACOPP carrying slightly better cure rates than the other two but at the cost of greater toxicity, including the development of secondary acute myeloid leukemia/myelodysplastic syndrome and sterility. In 2018, the FDA approved brentuximab vedotin (CD30 targeted antibody-drug conjugate) in combination with AVD chemotherapy for first-line treatment of stage III or IV classical HL. [15] Systemic chemotherapy is supplemented by local radiation either because of bulky disease or persistent PET/CT positivity after chemotherapy. [1] [2] [16]", "contents": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]. Standard treatment in the United States (US) consists of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). In Germany, the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) is more popular. A third regimen that is used is Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone). All these regimens have similar response rates with BEACOPP carrying slightly better cure rates than the other two but at the cost of greater toxicity, including the development of secondary acute myeloid leukemia/myelodysplastic syndrome and sterility. In 2018, the FDA approved brentuximab vedotin (CD30 targeted antibody-drug conjugate) in combination with AVD chemotherapy for first-line treatment of stage III or IV classical HL. [15] Systemic chemotherapy is supplemented by local radiation either because of bulky disease or persistent PET/CT positivity after chemotherapy. [1] [2] [16]"}
{"id": "article-24580_114", "title": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]", "content": "Repeat imaging is done to assess the response to treatment, which consists of a PET/CT scan. PET/CT results are evaluated by Deavullie criteria whereby signal less than or equal to the physiologic signal from the liver is negative (1-3) and signal greater than the liver (4-5) is positive. A new strategy evolving in both the United States and Europe is to start the initial treatment with ABVD, monitor response to chemotherapy with repeat PET/CT after two cycles, then escalate the treatment to BEACOPP only for those patients with an incomplete response. [17] Recent indications are that if PET/CT response to ABVD is good, then bleomycin may be omitted from later cycles without compromising response, and avoiding unnecessary pulmonary toxicity.", "contents": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]. Repeat imaging is done to assess the response to treatment, which consists of a PET/CT scan. PET/CT results are evaluated by Deavullie criteria whereby signal less than or equal to the physiologic signal from the liver is negative (1-3) and signal greater than the liver (4-5) is positive. A new strategy evolving in both the United States and Europe is to start the initial treatment with ABVD, monitor response to chemotherapy with repeat PET/CT after two cycles, then escalate the treatment to BEACOPP only for those patients with an incomplete response. [17] Recent indications are that if PET/CT response to ABVD is good, then bleomycin may be omitted from later cycles without compromising response, and avoiding unnecessary pulmonary toxicity."}
{"id": "article-24580_115", "title": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]", "content": "Upon completion of therapy, patients are evaluated\u00a0as part of surveillance at regular intervals to exclude disease recurrence, with history & physical and basic laboratory tests, but without routine repeat imaging. Because many patients with HL are young and cured, they will live for a long time after treatment and must be monitored for the sequelae of the treatment especially the development of secondary cancers within previous radiation fields, such as lung, breast, or thyroid, as well as coronary artery disease.", "contents": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]. Upon completion of therapy, patients are evaluated\u00a0as part of surveillance at regular intervals to exclude disease recurrence, with history & physical and basic laboratory tests, but without routine repeat imaging. Because many patients with HL are young and cured, they will live for a long time after treatment and must be monitored for the sequelae of the treatment especially the development of secondary cancers within previous radiation fields, such as lung, breast, or thyroid, as well as coronary artery disease."}
{"id": "article-24580_116", "title": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]", "content": "For patients with resistant or relapsed HL, several salvage regimens are available. Brentuximab vedotin is also approved by the FDA as a second-line agent. Salvage therapy, if successful, is followed by consolidation with high dose chemotherapy and autologous stem cell rescue. In cases where the disease is fully resistant or relapses again after autologous stem cell rescue, experimental agents within the context of a clinical trial are indicated, or, in selected cases, allogeneic stem cell transplantation. [1] [2] [18]", "contents": "Lymphoma -- Treatment / Management -- Hodgkin Lymphoma [14]. For patients with resistant or relapsed HL, several salvage regimens are available. Brentuximab vedotin is also approved by the FDA as a second-line agent. Salvage therapy, if successful, is followed by consolidation with high dose chemotherapy and autologous stem cell rescue. In cases where the disease is fully resistant or relapses again after autologous stem cell rescue, experimental agents within the context of a clinical trial are indicated, or, in selected cases, allogeneic stem cell transplantation. [1] [2] [18]"}
{"id": "article-24580_117", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "Many patients with DLBCL achieve a long term disease-free status with aggressive combination chemotherapy. The gold standard for DLBCL treatment is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). [1] [2] [19]", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. Many patients with DLBCL achieve a long term disease-free status with aggressive combination chemotherapy. The gold standard for DLBCL treatment is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). [1] [2] [19]"}
{"id": "article-24580_118", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "For localized disease, combination chemoradiation therapy can be used, with three cycles of systemic chemotherapy supplemented by\u00a0involved field radiation therapy (IFRT)\u00a0with the purpose of limiting overall exposure to the chemotherapy. For patients with poor performance status, milder treatment options include R-mini CHOP (reduced doses of all drugs except rituximab), R-CHOP minus doxorubicin (R\u2013CVP), or single-agent rituximab. [1] [2] [20] [21]", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. For localized disease, combination chemoradiation therapy can be used, with three cycles of systemic chemotherapy supplemented by\u00a0involved field radiation therapy (IFRT)\u00a0with the purpose of limiting overall exposure to the chemotherapy. For patients with poor performance status, milder treatment options include R-mini CHOP (reduced doses of all drugs except rituximab), R-CHOP minus doxorubicin (R\u2013CVP), or single-agent rituximab. [1] [2] [20] [21]"}
{"id": "article-24580_119", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "Special consideration should be given to cardiac comorbidities due to the cardiac toxicity of doxorubicin, an anthracycline. Baseline echocardiography or multi gated acquisition (MUGA) scan should be performed before initiation of chemotherapy.", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. Special consideration should be given to cardiac comorbidities due to the cardiac toxicity of doxorubicin, an anthracycline. Baseline echocardiography or multi gated acquisition (MUGA) scan should be performed before initiation of chemotherapy."}
{"id": "article-24580_120", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "For a subgroup of DLBCL, categorized as double hit or triple hit lymphomas (based on rearrangements of two or three genes: c-MYC, BCL-2, and BCL-6), the prognosis is poor, and they tend to carry morphologic, biologic and cytogenetic properties similar to both DLBCL and much aggressive BL. There is a lack of data regarding the optimal chemotherapy regimen for such lymphomas but are usually treated with more intense chemotherapy regimens, similar to those used in the management of BL.", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. For a subgroup of DLBCL, categorized as double hit or triple hit lymphomas (based on rearrangements of two or three genes: c-MYC, BCL-2, and BCL-6), the prognosis is poor, and they tend to carry morphologic, biologic and cytogenetic properties similar to both DLBCL and much aggressive BL. There is a lack of data regarding the optimal chemotherapy regimen for such lymphomas but are usually treated with more intense chemotherapy regimens, similar to those used in the management of BL."}
{"id": "article-24580_121", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "Reimaging by PET/CT is recommended to assess for treatment response at the end of the treatment. Interval assessment is also done during treatment, after 2 to 4 cycles of chemotherapy, with the purpose of identifying those cases not responding to initial chemotherapy. Patients who complete successful therapy should be followed at regular intervals as part of surveillance. Follow-up consists of history and physical examination, with basic laboratory tests (complete blood counts, metabolic panel, liver function tests, and lactate dehydrogenase). Repeat imaging is not needed routinely, in the absence of specific concerns. Most disease relapse occurs within two years, such that the follow-up interval is spaced out if the disease remains in remission beyond five years.", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. Reimaging by PET/CT is recommended to assess for treatment response at the end of the treatment. Interval assessment is also done during treatment, after 2 to 4 cycles of chemotherapy, with the purpose of identifying those cases not responding to initial chemotherapy. Patients who complete successful therapy should be followed at regular intervals as part of surveillance. Follow-up consists of history and physical examination, with basic laboratory tests (complete blood counts, metabolic panel, liver function tests, and lactate dehydrogenase). Repeat imaging is not needed routinely, in the absence of specific concerns. Most disease relapse occurs within two years, such that the follow-up interval is spaced out if the disease remains in remission beyond five years."}
{"id": "article-24580_122", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "Clinical trials are currently underway to assess the efficacy and safety of adding immunomodulatory agents (lenalidomide) or Bruton\u2019s tyrosine kinase inhibitors (ibrutinib) to R-CHOP in previously untreated DLBCL. [22] [23]", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. Clinical trials are currently underway to assess the efficacy and safety of adding immunomodulatory agents (lenalidomide) or Bruton\u2019s tyrosine kinase inhibitors (ibrutinib) to R-CHOP in previously untreated DLBCL. [22] [23]"}
{"id": "article-24580_123", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "For those cases\u00a0which do not respond or relapse after first-line chemotherapy, several higher-intensity chemotherapy regimens are used as salvage therapy. Common second-line regimens include R-ICE (rituximab, ifosfamide, carboplatin, etoposide), R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin)\u00a0 which are more intense than R- CHOP and require inpatient administration of chemotherapy drugs. Survival after successful salvage therapy for resistant/relapsed DLBCL is improved significantly if salvage therapy is followed by high dose chemotherapy with autologous stem cell rescue (HD-SCT) consolidation.", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. For those cases\u00a0which do not respond or relapse after first-line chemotherapy, several higher-intensity chemotherapy regimens are used as salvage therapy. Common second-line regimens include R-ICE (rituximab, ifosfamide, carboplatin, etoposide), R-DHAP (rituximab, dexamethasone, cytarabine, cisplatin)\u00a0 which are more intense than R- CHOP and require inpatient administration of chemotherapy drugs. Survival after successful salvage therapy for resistant/relapsed DLBCL is improved significantly if salvage therapy is followed by high dose chemotherapy with autologous stem cell rescue (HD-SCT) consolidation."}
{"id": "article-24580_124", "title": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma", "content": "The benefit of HD-SCT lies in the use of high doses of chemotherapy. A harvest of autologous peripheral blood stem cells before administration of high-dose chemotherapy allows for the use of chemotherapy doses, which are so bone marrow toxic that they would otherwise kill the patient, were it not for rescue by stem cell reinfusion. In cases where second-line therapies fail, clinical trials or allogeneic stem cell transplantation may be considered. [24] The latest advance in the management of relapsed/refractory DLBCL is the utilization of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. [25] [26]", "contents": "Lymphoma -- Treatment / Management -- Diffuse Large B- Cell Lymphoma. The benefit of HD-SCT lies in the use of high doses of chemotherapy. A harvest of autologous peripheral blood stem cells before administration of high-dose chemotherapy allows for the use of chemotherapy doses, which are so bone marrow toxic that they would otherwise kill the patient, were it not for rescue by stem cell reinfusion. In cases where second-line therapies fail, clinical trials or allogeneic stem cell transplantation may be considered. [24] The latest advance in the management of relapsed/refractory DLBCL is the utilization of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. [25] [26]"}
{"id": "article-24580_125", "title": "Lymphoma -- Treatment / Management -- Follicular Lymphoma", "content": "As an indolent slow-growing lymphoma, the clinical behavior of FL is variable. While some cases of FL remain asymptomatic, even being untreated, or wax and wane on their own, others progress and cause significant symptoms. Asymptomatic FL can be managed by close observation, that is, monitoring for appearance of signs of progression or significant symptoms before any intervention is planned. Treatment is usually not considered to be curative, so it must be chosen judiciously, weighing benefits against toxicities and the fact that after multiple therapies, toxicity will be cumulative. [27]", "contents": "Lymphoma -- Treatment / Management -- Follicular Lymphoma. As an indolent slow-growing lymphoma, the clinical behavior of FL is variable. While some cases of FL remain asymptomatic, even being untreated, or wax and wane on their own, others progress and cause significant symptoms. Asymptomatic FL can be managed by close observation, that is, monitoring for appearance of signs of progression or significant symptoms before any intervention is planned. Treatment is usually not considered to be curative, so it must be chosen judiciously, weighing benefits against toxicities and the fact that after multiple therapies, toxicity will be cumulative. [27]"}
{"id": "article-24580_126", "title": "Lymphoma -- Treatment / Management -- Follicular Lymphoma", "content": "For localized FL confined to 1 lymph node area, radiotherapy may be chosen as the single modality of therapy. More commonly, several areas within the body are involved in FL, and systemic therapy is needed. Usually, a less aggressive approach such as single-agent rituximab may be chosen as first-line therapy, even for patients with good performance status, thus reserving the option of escalation in therapy for future needs. For higher disease burden FL, systemic cytotoxic chemotherapy is used. In FL, a number of different regimens have been used over the years.", "contents": "Lymphoma -- Treatment / Management -- Follicular Lymphoma. For localized FL confined to 1 lymph node area, radiotherapy may be chosen as the single modality of therapy. More commonly, several areas within the body are involved in FL, and systemic therapy is needed. Usually, a less aggressive approach such as single-agent rituximab may be chosen as first-line therapy, even for patients with good performance status, thus reserving the option of escalation in therapy for future needs. For higher disease burden FL, systemic cytotoxic chemotherapy is used. In FL, a number of different regimens have been used over the years."}
{"id": "article-24580_127", "title": "Lymphoma -- Treatment / Management -- Follicular Lymphoma", "content": "Since overall survival in FL is measured in decades, it is difficult to show the superiority of 1 regimen over another. Recently, rituximab-bendamustine (R- Benda) has emerged as the most popular treatment, being superior to R-CHOP in terms of progression-free survival. [28]", "contents": "Lymphoma -- Treatment / Management -- Follicular Lymphoma. Since overall survival in FL is measured in decades, it is difficult to show the superiority of 1 regimen over another. Recently, rituximab-bendamustine (R- Benda) has emerged as the most popular treatment, being superior to R-CHOP in terms of progression-free survival. [28]"}
{"id": "article-24580_128", "title": "Lymphoma -- Treatment / Management -- Follicular Lymphoma", "content": "Maintenance rituximab after completion of frontline systemic chemotherapy, usually once every two months for two years, has been shown to prolong progression-free survival but not overall survival. [29]", "contents": "Lymphoma -- Treatment / Management -- Follicular Lymphoma. Maintenance rituximab after completion of frontline systemic chemotherapy, usually once every two months for two years, has been shown to prolong progression-free survival but not overall survival. [29]"}
{"id": "article-24580_129", "title": "Lymphoma -- Treatment / Management -- Follicular Lymphoma", "content": "As an incurable disease, relapse of FL is anticipated at some point in clinical course and can be treated with the other regimens at frontline treatment. Upon recurrence of all indolent lymphomas, the possibility of transformation to aggressive lymphoma should be excluded. In cases where FL relapses early or show aggressive features, HD-SCT or allogeneic transplantation can be considered.", "contents": "Lymphoma -- Treatment / Management -- Follicular Lymphoma. As an incurable disease, relapse of FL is anticipated at some point in clinical course and can be treated with the other regimens at frontline treatment. Upon recurrence of all indolent lymphomas, the possibility of transformation to aggressive lymphoma should be excluded. In cases where FL relapses early or show aggressive features, HD-SCT or allogeneic transplantation can be considered."}
{"id": "article-24580_130", "title": "Lymphoma -- Treatment / Management -- Marginal Zone Lymphoma", "content": "In many circumstances, the treatment of marginal zone lymphomas (MZL) is similar to FL, but it differs in certain specific scenarios. For early-stage gastric MALT lymphoma, eradication of H.pylori in patients with favorable cytogenetics results in tumor regression or remission in 50-80% of patients. Patients with limited disease in whom H.pylori eradication is ineffective, are also cured usually with definitive radiotherapy.", "contents": "Lymphoma -- Treatment / Management -- Marginal Zone Lymphoma. In many circumstances, the treatment of marginal zone lymphomas (MZL) is similar to FL, but it differs in certain specific scenarios. For early-stage gastric MALT lymphoma, eradication of H.pylori in patients with favorable cytogenetics results in tumor regression or remission in 50-80% of patients. Patients with limited disease in whom H.pylori eradication is ineffective, are also cured usually with definitive radiotherapy."}
{"id": "article-24580_131", "title": "Lymphoma -- Treatment / Management -- Marginal Zone Lymphoma", "content": "Another important divergence from routine management of FL exists for splenic MZL. For patients with symptomatic splenomegaly and associated cytopenias, surgical splenectomy results in normalization of cell counts and helps to achieve disease stabilization and systemic regression. Single-agent rituximab therapy is also an approved non-surgical treatment alternative.", "contents": "Lymphoma -- Treatment / Management -- Marginal Zone Lymphoma. Another important divergence from routine management of FL exists for splenic MZL. For patients with symptomatic splenomegaly and associated cytopenias, surgical splenectomy results in normalization of cell counts and helps to achieve disease stabilization and systemic regression. Single-agent rituximab therapy is also an approved non-surgical treatment alternative."}
{"id": "article-24580_132", "title": "Lymphoma -- Treatment / Management -- Mantle Cell Lymphoma", "content": "Treatment of the less aggressive disease is with either R- CHOP or R- Benda, followed by maintenance rituximab. Most patients also need more intensive treatment regimens. One agent cytarabine is included in most regimens due to its activity in mantle cell lymphoma. The front line chemotherapy is followed in the first remission by consolidation with high dose chemotherapy and autologous stem cell transplantation. One such approach is the Nordic protocol (a maxi R\u2013CHOP regimen alternating with rituximab and high-dose cytarabine). Another regimen is alternating hyper CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) with methotrexate/cytarabine. Lenalidomide and bortezomib have single-agent activity in relapsed MCL. The Bruton\u2019s tyrosine kinase inhibitor, Ibrutinib, is approved by the FDA for use in relapsed MCL as it has good activity in MCL. [14]", "contents": "Lymphoma -- Treatment / Management -- Mantle Cell Lymphoma. Treatment of the less aggressive disease is with either R- CHOP or R- Benda, followed by maintenance rituximab. Most patients also need more intensive treatment regimens. One agent cytarabine is included in most regimens due to its activity in mantle cell lymphoma. The front line chemotherapy is followed in the first remission by consolidation with high dose chemotherapy and autologous stem cell transplantation. One such approach is the Nordic protocol (a maxi R\u2013CHOP regimen alternating with rituximab and high-dose cytarabine). Another regimen is alternating hyper CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) with methotrexate/cytarabine. Lenalidomide and bortezomib have single-agent activity in relapsed MCL. The Bruton\u2019s tyrosine kinase inhibitor, Ibrutinib, is approved by the FDA for use in relapsed MCL as it has good activity in MCL. [14]"}
{"id": "article-24580_133", "title": "Lymphoma -- Treatment / Management -- Burkitt Lymphoma", "content": "BL\u00a0should be approached as an oncologic emergency due to a high proliferation rate of the tumor. This high proliferation rate requires immediate treatment with aggressive chemotherapy regimens in which the intensity of delivery is meant to outpace the capacity for the cellular division to prevent the development of tumor resistance. Failure to do so can result in rapid tumor proliferation, end-organ damage, and death. If treatment is initiated in a timely manner, results are favorable. Treatment options for BL include R-hyper CVAD-methotrexate/cytarabine and R-CODOX-M/IVAC (rituximab, cyclophosphamide, vincristine, doxorubicin, methotrexate/ ifosfamide, etoposide, cytarabine). Recently, DA-R-EPOCH (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) a more intense and easier to tolerate regimen has shown good results. These intense regimens are associated with complete remission rates of approximately 80 to 90% and disease-free survival rates of 50-75%. [30]", "contents": "Lymphoma -- Treatment / Management -- Burkitt Lymphoma. BL\u00a0should be approached as an oncologic emergency due to a high proliferation rate of the tumor. This high proliferation rate requires immediate treatment with aggressive chemotherapy regimens in which the intensity of delivery is meant to outpace the capacity for the cellular division to prevent the development of tumor resistance. Failure to do so can result in rapid tumor proliferation, end-organ damage, and death. If treatment is initiated in a timely manner, results are favorable. Treatment options for BL include R-hyper CVAD-methotrexate/cytarabine and R-CODOX-M/IVAC (rituximab, cyclophosphamide, vincristine, doxorubicin, methotrexate/ ifosfamide, etoposide, cytarabine). Recently, DA-R-EPOCH (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) a more intense and easier to tolerate regimen has shown good results. These intense regimens are associated with complete remission rates of approximately 80 to 90% and disease-free survival rates of 50-75%. [30]"}
{"id": "article-24580_134", "title": "Lymphoma -- Treatment / Management -- Burkitt Lymphoma", "content": "With BL, obtaining a good response with the first attempt of treatment is of particular importance.", "contents": "Lymphoma -- Treatment / Management -- Burkitt Lymphoma. With BL, obtaining a good response with the first attempt of treatment is of particular importance."}
{"id": "article-24580_135", "title": "Lymphoma -- Treatment / Management -- Peripheral T- Cell Lymphoma (PTCL)", "content": "For different types of PTCL, there is no consensus on the treatment. Indolent slow-growing cutaneous T-cell lymphomas, including early-stage MF and cutaneous ALCL, can usually be monitored or treated with skin-directed treatments (topical medications, prednisone, ultraviolet therapy, involved-field radiotherapy) or mild systemic treatments such as retinoids. 18-FDG PET scanning is utilized in selected cases, mainly in the evaluation of cutaneous T-cell lymphoma, to identify the extracutaneous disease as it can change both prognosis and therapeutic approach. For the aggressive PTCLs, chemotherapy with multiple agents is used, such as CHOP, although with the exception of ALK-1 positive ALCL, where it is commonly associated with brief progression-free durations. For nasal NK/T-cell lymphoma, early incorporation of radiation therapy in a combined modality therapy results in better outcomes.", "contents": "Lymphoma -- Treatment / Management -- Peripheral T- Cell Lymphoma (PTCL). For different types of PTCL, there is no consensus on the treatment. Indolent slow-growing cutaneous T-cell lymphomas, including early-stage MF and cutaneous ALCL, can usually be monitored or treated with skin-directed treatments (topical medications, prednisone, ultraviolet therapy, involved-field radiotherapy) or mild systemic treatments such as retinoids. 18-FDG PET scanning is utilized in selected cases, mainly in the evaluation of cutaneous T-cell lymphoma, to identify the extracutaneous disease as it can change both prognosis and therapeutic approach. For the aggressive PTCLs, chemotherapy with multiple agents is used, such as CHOP, although with the exception of ALK-1 positive ALCL, where it is commonly associated with brief progression-free durations. For nasal NK/T-cell lymphoma, early incorporation of radiation therapy in a combined modality therapy results in better outcomes."}
{"id": "article-24580_136", "title": "Lymphoma -- Treatment / Management -- Peripheral T- Cell Lymphoma (PTCL)", "content": "For CD30 positive lymphomas, the antibody-drug conjugate brentuximab vedotin is effective. Histone deacetylase inhibitors such as romidepsin and belinostat have moderate activity in T- cell lymphoma. [1] [2] [11] [31]", "contents": "Lymphoma -- Treatment / Management -- Peripheral T- Cell Lymphoma (PTCL). For CD30 positive lymphomas, the antibody-drug conjugate brentuximab vedotin is effective. Histone deacetylase inhibitors such as romidepsin and belinostat have moderate activity in T- cell lymphoma. [1] [2] [11] [31]"}
{"id": "article-24580_137", "title": "Lymphoma -- Differential Diagnosis", "content": "Tuberculosis Sarcoidosis Beh\u00e7et disease [2] [32]", "contents": "Lymphoma -- Differential Diagnosis. Tuberculosis Sarcoidosis Beh\u00e7et disease [2] [32]"}
{"id": "article-24580_138", "title": "Lymphoma -- Radiation Oncology", "content": "For classic HL, radiation therapy (RT) is often used after chemotherapy for a residual, limited area of lymphadenopathy that is FDG avid on restaging PET/CT. RT by itself can be used to treat some cases of nodular lymphocyte-predominant HL. In NHL, RT can be used in various scenarios; For early-stage (Ann Arbor stage I or II) indolent NHL with a limited amount of disease burden, RT can be used as a single modality treatment. For more advanced and/or aggressive NHL, RT is used after chemotherapy as consolidation. Consensus recommendations/guidelines from the International Lymphoma Radiation Oncology Group (ILROG):", "contents": "Lymphoma -- Radiation Oncology. For classic HL, radiation therapy (RT) is often used after chemotherapy for a residual, limited area of lymphadenopathy that is FDG avid on restaging PET/CT. RT by itself can be used to treat some cases of nodular lymphocyte-predominant HL. In NHL, RT can be used in various scenarios; For early-stage (Ann Arbor stage I or II) indolent NHL with a limited amount of disease burden, RT can be used as a single modality treatment. For more advanced and/or aggressive NHL, RT is used after chemotherapy as consolidation. Consensus recommendations/guidelines from the International Lymphoma Radiation Oncology Group (ILROG):"}
{"id": "article-24580_139", "title": "Lymphoma -- Radiation Oncology", "content": "Positron emission tomography (PET)/computed tomography (CT) is recommended as the standard modality for staging and response assessment in fluorodeoxyglucose (FDG)-avid lymphomas, in line with the international Lugano guidelines. An accurate definition of sites of involvement before any systemic therapy is important for radiation therapy (RT) planning. Baseline pretreatment PET/CT is recommended as best practice.", "contents": "Lymphoma -- Radiation Oncology. Positron emission tomography (PET)/computed tomography (CT) is recommended as the standard modality for staging and response assessment in fluorodeoxyglucose (FDG)-avid lymphomas, in line with the international Lugano guidelines. An accurate definition of sites of involvement before any systemic therapy is important for radiation therapy (RT) planning. Baseline pretreatment PET/CT is recommended as best practice."}
{"id": "article-24580_140", "title": "Lymphoma -- Radiation Oncology", "content": "Radiation oncologists should familiarize themselves with the limitations of FDG imaging and recognize conditions that mimic lymphoma, such as brown fat; physiologic uptake in tonsils, nasopharynx, or salivary glands; inflammatory uptake; benign tumors of parotids; sarcoidosis; thymic hyperplasia; and physiologic bone marrow uptake.", "contents": "Lymphoma -- Radiation Oncology. Radiation oncologists should familiarize themselves with the limitations of FDG imaging and recognize conditions that mimic lymphoma, such as brown fat; physiologic uptake in tonsils, nasopharynx, or salivary glands; inflammatory uptake; benign tumors of parotids; sarcoidosis; thymic hyperplasia; and physiologic bone marrow uptake."}
{"id": "article-24580_141", "title": "Lymphoma -- Radiation Oncology", "content": "Magnetic resonance imaging (MRI) is indicated in certain anatomic areas: central nervous system, head (orbits, nose/paranasal sinuses, and skull base), and skeletal sites.", "contents": "Lymphoma -- Radiation Oncology. Magnetic resonance imaging (MRI) is indicated in certain anatomic areas: central nervous system, head (orbits, nose/paranasal sinuses, and skull base), and skeletal sites."}
{"id": "article-24580_142", "title": "Lymphoma -- Radiation Oncology", "content": "The use of a 5-point score (known as Deauville criteria) is recommended for response assessment, in line with the international Lugano guidelines.", "contents": "Lymphoma -- Radiation Oncology. The use of a 5-point score (known as Deauville criteria) is recommended for response assessment, in line with the international Lugano guidelines."}
{"id": "article-24580_143", "title": "Lymphoma -- Radiation Oncology", "content": "Deauville score 3 requires cautious interpretation, with consideration given to clinical context, histological type, disease stage, bulk, and estimated prognosis, as well as the results of clinical trials. In some clinical trials using a de-escalation strategy with the omission of RT, Deauville score three was not considered a complete metabolic response.", "contents": "Lymphoma -- Radiation Oncology. Deauville score 3 requires cautious interpretation, with consideration given to clinical context, histological type, disease stage, bulk, and estimated prognosis, as well as the results of clinical trials. In some clinical trials using a de-escalation strategy with the omission of RT, Deauville score three was not considered a complete metabolic response."}
{"id": "article-24580_144", "title": "Lymphoma -- Radiation Oncology", "content": "When defining RT targets based on PET/CT, the clinician should carefully consider the anatomical information from the CT part of the scan because some small involved nodes with low FDG uptake may be below the PET detection limit.", "contents": "Lymphoma -- Radiation Oncology. When defining RT targets based on PET/CT, the clinician should carefully consider the anatomical information from the CT part of the scan because some small involved nodes with low FDG uptake may be below the PET detection limit."}
{"id": "article-24580_145", "title": "Lymphoma -- Radiation Oncology", "content": "Smaller nodes that are not FDG-avid but seen on CT adjacent to (or between) FDG-avid nodes, and judged to be involved, should be included in the target volume. For CT masses with partial FDG uptake, the entire mass should be included in the target volume.", "contents": "Lymphoma -- Radiation Oncology. Smaller nodes that are not FDG-avid but seen on CT adjacent to (or between) FDG-avid nodes, and judged to be involved, should be included in the target volume. For CT masses with partial FDG uptake, the entire mass should be included in the target volume."}
{"id": "article-24580_146", "title": "Lymphoma -- Radiation Oncology", "content": "Residual FDG-avid areas can be treated to higher doses using an integrated boost technique.", "contents": "Lymphoma -- Radiation Oncology. Residual FDG-avid areas can be treated to higher doses using an integrated boost technique."}
{"id": "article-24580_147", "title": "Lymphoma -- Radiation Oncology", "content": "Thin-slice CT should be performed in the chosen treatment position, using immobilization devices if required, and should include relevant organs at risk as a whole. Intravenous contrast is recommended to help identify blood vessels and enhance soft-tissue definition.", "contents": "Lymphoma -- Radiation Oncology. Thin-slice CT should be performed in the chosen treatment position, using immobilization devices if required, and should include relevant organs at risk as a whole. Intravenous contrast is recommended to help identify blood vessels and enhance soft-tissue definition."}
{"id": "article-24580_148", "title": "Lymphoma -- Radiation Oncology", "content": "Breathing-control techniques (e.g., deep inspiration breath-hold) are recommended as best practice for mediastinal treatment to help reduce organ-at-risk doses.", "contents": "Lymphoma -- Radiation Oncology. Breathing-control techniques (e.g., deep inspiration breath-hold) are recommended as best practice for mediastinal treatment to help reduce organ-at-risk doses."}
{"id": "article-24580_149", "title": "Lymphoma -- Radiation Oncology", "content": "PET/CT is highly recommended as best practice for planning modern radiation volumes, according to the involved node or involved site RT concepts.", "contents": "Lymphoma -- Radiation Oncology. PET/CT is highly recommended as best practice for planning modern radiation volumes, according to the involved node or involved site RT concepts."}
{"id": "article-24580_150", "title": "Lymphoma -- Radiation Oncology", "content": "If RT is the sole modality of treatment, a dedicated planning PET/CT can be performed in the treatment position, with the use of immobilization devices if required.", "contents": "Lymphoma -- Radiation Oncology. If RT is the sole modality of treatment, a dedicated planning PET/CT can be performed in the treatment position, with the use of immobilization devices if required."}
{"id": "article-24580_151", "title": "Lymphoma -- Radiation Oncology", "content": "If chemotherapy is given before RT, it is recommended that the prechemotherapy PET/CT be performed in a position similar to RT position to enable accurate coregistration with the planning CT and outlining of involved node RT volumes.", "contents": "Lymphoma -- Radiation Oncology. If chemotherapy is given before RT, it is recommended that the prechemotherapy PET/CT be performed in a position similar to RT position to enable accurate coregistration with the planning CT and outlining of involved node RT volumes."}
{"id": "article-24580_152", "title": "Lymphoma -- Radiation Oncology", "content": "If the prechemotherapy PET/CT cannot be obtained in the treatment position and accurate coregistration is not possible, the concept of involved site RT as described in other International Lymphoma Radiation Oncology Group guidelines should be used to account for the lack of optimal prechemotherapy imaging.", "contents": "Lymphoma -- Radiation Oncology. If the prechemotherapy PET/CT cannot be obtained in the treatment position and accurate coregistration is not possible, the concept of involved site RT as described in other International Lymphoma Radiation Oncology Group guidelines should be used to account for the lack of optimal prechemotherapy imaging."}
{"id": "article-24580_153", "title": "Lymphoma -- Radiation Oncology", "content": "In sites where MRI is useful, both PET/CT and MRI scans should be coregistered with planning CT scans to guide target volume definition.", "contents": "Lymphoma -- Radiation Oncology. In sites where MRI is useful, both PET/CT and MRI scans should be coregistered with planning CT scans to guide target volume definition."}
{"id": "article-24580_154", "title": "Lymphoma -- Radiation Oncology", "content": "Image-guided radiotherapy, particularly using cone-beam CT, is recommended with modern RT techniques, which use small target volumes and steep dose gradients, to ensure accuracy of treatment delivery.", "contents": "Lymphoma -- Radiation Oncology. Image-guided radiotherapy, particularly using cone-beam CT, is recommended with modern RT techniques, which use small target volumes and steep dose gradients, to ensure accuracy of treatment delivery."}
{"id": "article-24580_155", "title": "Lymphoma -- Radiation Oncology", "content": "The frequency of imaging has not been studied carefully in the context of lymphoma, and individual departments should decide on the frequency of imaging based on local setup accuracy data, margins used to create the planning target volume, specific treatment site, and use of immobilization devices. [33]", "contents": "Lymphoma -- Radiation Oncology. The frequency of imaging has not been studied carefully in the context of lymphoma, and individual departments should decide on the frequency of imaging based on local setup accuracy data, margins used to create the planning target volume, specific treatment site, and use of immobilization devices. [33]"}
{"id": "article-24580_156", "title": "Lymphoma -- Staging", "content": "The clinical staging of both HL and NHL derive from the Ann Arbor (AA) staging system, which was subsequently modified at the Cotswolds meeting in 1989. The modification kept the previous four-stage system, with the addition of the modifier \u2018\u2018X\u2019\u2019 for bulk, defined as greater than 10 cm in long-axis or for a mediastinal mass as measuring greater than one-third of the internal transverse thoracic diameter of a standard PA chest X-ray at the level of the fifth or sixth thoracic vertebral body. It is based on the extent of involvement of lymph node groups. The \u2018\u2018E\u2019\u2019 modifier presents a direct extension of the tumor to an extranodal site, or for stage IE disease, isolated involvement of a single extranodal site without evidence of lymph node disease (e.g., primary lymphoma of bone or thyroid). The \u2018\u2018B\u2019\u2019 modifier refers to the presence of one or more of a set of symptoms that are associated with more aggressive disease and worse prognosis, and these include unexplained recurring or persistent fever, drenching night sweats, or unexplained weight loss of 10% of body weight (B symptoms).", "contents": "Lymphoma -- Staging. The clinical staging of both HL and NHL derive from the Ann Arbor (AA) staging system, which was subsequently modified at the Cotswolds meeting in 1989. The modification kept the previous four-stage system, with the addition of the modifier \u2018\u2018X\u2019\u2019 for bulk, defined as greater than 10 cm in long-axis or for a mediastinal mass as measuring greater than one-third of the internal transverse thoracic diameter of a standard PA chest X-ray at the level of the fifth or sixth thoracic vertebral body. It is based on the extent of involvement of lymph node groups. The \u2018\u2018E\u2019\u2019 modifier presents a direct extension of the tumor to an extranodal site, or for stage IE disease, isolated involvement of a single extranodal site without evidence of lymph node disease (e.g., primary lymphoma of bone or thyroid). The \u2018\u2018B\u2019\u2019 modifier refers to the presence of one or more of a set of symptoms that are associated with more aggressive disease and worse prognosis, and these include unexplained recurring or persistent fever, drenching night sweats, or unexplained weight loss of 10% of body weight (B symptoms)."}
{"id": "article-24580_157", "title": "Lymphoma -- Staging", "content": "Cotswolds modification of the Ann Arbor staging system:", "contents": "Lymphoma -- Staging. Cotswolds modification of the Ann Arbor staging system:"}
{"id": "article-24580_158", "title": "Lymphoma -- Staging -- Stage I", "content": "Involvement of a single lymph node region or lymphoid structure (e.g., spleen, thymus, Waldeyer\u2019s ring) or involvement of a single extra lymphatic site (IE)", "contents": "Lymphoma -- Staging -- Stage I. Involvement of a single lymph node region or lymphoid structure (e.g., spleen, thymus, Waldeyer\u2019s ring) or involvement of a single extra lymphatic site (IE)"}
{"id": "article-24580_159", "title": "Lymphoma -- Staging -- Stage II", "content": "Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized contiguous involvement of only one extranodal organ or side and its regional lymph-nodes with or without other lymph node regions on the same side of the diaphragm (IIE)Note: The number of anatomic regions involved may be indicated by a subscript (e.g., II3)", "contents": "Lymphoma -- Staging -- Stage II. Involvement of two or more lymph node regions on the same side of the diaphragm (II) or localized contiguous involvement of only one extranodal organ or side and its regional lymph-nodes with or without other lymph node regions on the same side of the diaphragm (IIE)Note: The number of anatomic regions involved may be indicated by a subscript (e.g., II3)"}
{"id": "article-24580_160", "title": "Lymphoma -- Staging -- Stage III", "content": "Involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by involvement of the spleen (IIIS) or by localized contiguous involvement of only one extranodal organ side (IIIE) or both (IIISE)", "contents": "Lymphoma -- Staging -- Stage III. Involvement of lymph node regions on both sides of the diaphragm (III), which may also be accompanied by involvement of the spleen (IIIS) or by localized contiguous involvement of only one extranodal organ side (IIIE) or both (IIISE)"}
{"id": "article-24580_161", "title": "Lymphoma -- Staging -- Stage IV", "content": "Disseminated (multifocal) involvement of one or more extranodal organs or tissues, with or without associated lymph-node involvement or isolated extra lymphatic organ involvement with distant (non-regional) nodal involvement", "contents": "Lymphoma -- Staging -- Stage IV. Disseminated (multifocal) involvement of one or more extranodal organs or tissues, with or without associated lymph-node involvement or isolated extra lymphatic organ involvement with distant (non-regional) nodal involvement"}
{"id": "article-24580_162", "title": "Lymphoma -- Staging -- Designations Applicable to Any Disease Stage", "content": "A: No symptomsB: Fever (temperature > 38 C), drenching night sweats, unexplained loss of more than 10% of body weight during the previous six months.X: Bulky diseaseE: Involvement of an extranodal site that is contiguous or proximal to the known nodal site [1] [2]", "contents": "Lymphoma -- Staging -- Designations Applicable to Any Disease Stage. A: No symptomsB: Fever (temperature > 38 C), drenching night sweats, unexplained loss of more than 10% of body weight during the previous six months.X: Bulky diseaseE: Involvement of an extranodal site that is contiguous or proximal to the known nodal site [1] [2]"}
{"id": "article-24580_163", "title": "Lymphoma -- Prognosis", "content": "Due to the limited predictive power of Ann Arbor staging for both HL and NHL, clinical prognostic models are developed to help clinicians in conveying prognostic information to patients. Several models have been developed, which include\u00a0HL international prognostic score, international prognostic index (IPI) for DLBCL, and\u00a0FL international prognostic index (FLIPI) for follicular lymphoma. Low IPI score predicts a better outcome and high IPI a worse outcome. [2] [34] [35]", "contents": "Lymphoma -- Prognosis. Due to the limited predictive power of Ann Arbor staging for both HL and NHL, clinical prognostic models are developed to help clinicians in conveying prognostic information to patients. Several models have been developed, which include\u00a0HL international prognostic score, international prognostic index (IPI) for DLBCL, and\u00a0FL international prognostic index (FLIPI) for follicular lymphoma. Low IPI score predicts a better outcome and high IPI a worse outcome. [2] [34] [35]"}
{"id": "article-24580_164", "title": "Lymphoma -- Complications -- HL Complications", "content": "Paraneoplastic syndromes: Limbic encephalitis (anti-metabotropic glutamate receptor 5 (mGluR5) antibodies), primary CNS angiitis, cerebellar degeneration (anti-Tr antibodies), POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) [1] [36] [37]", "contents": "Lymphoma -- Complications -- HL Complications. Paraneoplastic syndromes: Limbic encephalitis (anti-metabotropic glutamate receptor 5 (mGluR5) antibodies), primary CNS angiitis, cerebellar degeneration (anti-Tr antibodies), POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes) [1] [36] [37]"}
{"id": "article-24580_165", "title": "Lymphoma -- Complications -- NHL Complications", "content": "Transformation of indolent lymphomas such as follicular lymphoma, marginal zone lymphoma into more aggressive NHL such as diffuse large B-cell lymphoma", "contents": "Lymphoma -- Complications -- NHL Complications. Transformation of indolent lymphomas such as follicular lymphoma, marginal zone lymphoma into more aggressive NHL such as diffuse large B-cell lymphoma"}
{"id": "article-24580_166", "title": "Lymphoma -- Complications -- Chemotherapy Complications", "content": "Pancytopenias, sterility, cardiomyopathy(doxorubicin), pneumonitis (bleomycin), neuropathy (vincristine, brentuximab vedotin), and second primary malignancies (acute myeloblastic leukemia, acute lymphoblastic leukemia).", "contents": "Lymphoma -- Complications -- Chemotherapy Complications. Pancytopenias, sterility, cardiomyopathy(doxorubicin), pneumonitis (bleomycin), neuropathy (vincristine, brentuximab vedotin), and second primary malignancies (acute myeloblastic leukemia, acute lymphoblastic leukemia)."}
{"id": "article-24580_167", "title": "Lymphoma -- Complications -- Radiotherapy Complications", "content": "Accelerated atherosclerosis, pericardial fibrosis, second primary cancers (lung, thyroid, breast, soft tissue sarcomas), and hypothyroidism [1] [36]", "contents": "Lymphoma -- Complications -- Radiotherapy Complications. Accelerated atherosclerosis, pericardial fibrosis, second primary cancers (lung, thyroid, breast, soft tissue sarcomas), and hypothyroidism [1] [36]"}
{"id": "article-24580_168", "title": "Lymphoma -- Deterrence and Patient Education", "content": "Lymphomas are one of the common cancers of our immune system. It makes up to almost 5% of all cancers. It can affect both young and older adults. The common symptoms of this disease are persistent fevers, drenching night sweats, unintentional weight loss, and generalized or localized swelling of the lymph nodes. If any of these symptoms are observed, the primary care provider seeks a hematology consultation or opinion as soon as possible for timely diagnosis and treatment, since timely identification and treatment of lymphomas result in better survival rates with the least number of complications.", "contents": "Lymphoma -- Deterrence and Patient Education. Lymphomas are one of the common cancers of our immune system. It makes up to almost 5% of all cancers. It can affect both young and older adults. The common symptoms of this disease are persistent fevers, drenching night sweats, unintentional weight loss, and generalized or localized swelling of the lymph nodes. If any of these symptoms are observed, the primary care provider seeks a hematology consultation or opinion as soon as possible for timely diagnosis and treatment, since timely identification and treatment of lymphomas result in better survival rates with the least number of complications."}
{"id": "article-24580_169", "title": "Lymphoma -- Enhancing Healthcare Team Outcomes", "content": "While a hematologist is almost always involved in the care of patients with lymphoma, it is important to consult with an interprofessional team of specialists that include a radiologist, radiation oncologist, pathologist, and a surgical oncologist. The nurses are also vital members of the interprofessional group as they monitor the patient vital signs and assist with patient and family education. Having oncology trained social workers and psychologists as part of an interdisciplinary team also plays a significant role in addressing psycho-social issues pertaining to the diagnosis and management of lymphomas, especially in young patients.", "contents": "Lymphoma -- Enhancing Healthcare Team Outcomes. While a hematologist is almost always involved in the care of patients with lymphoma, it is important to consult with an interprofessional team of specialists that include a radiologist, radiation oncologist, pathologist, and a surgical oncologist. The nurses are also vital members of the interprofessional group as they monitor the patient vital signs and assist with patient and family education. Having oncology trained social workers and psychologists as part of an interdisciplinary team also plays a significant role in addressing psycho-social issues pertaining to the diagnosis and management of lymphomas, especially in young patients."}
{"id": "article-24580_170", "title": "Lymphoma -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Lymphoma -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}